Skip to content

ASBP

Aspire Biopharma Holdings, Inc.

NASDAQ · Healthcare · Biotechnology · US

$8.41
−4.21%
Ask drillr

Year over year

Reported trailing growth

Revenue
—
EBITDA
+112.5%
EBIT
+58.8%
EPS
+74.5%
Free cash flow
—
Operating cash flow
—

Forward estimates

Based on analyst estimates

Revenue
—
EBITDA
—
EPS
—

Three-year CAGR

Revenue
—
EBITDA
—
EBIT
—
Net income
—
EPS
+52.1%
Free cash flow
—

Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026